

**Optimizing Outcomes in Newly Diagnosed Multiple Myeloma:
The Role of CD38 Monoclonal Antibodies
Clinical Brief 3 – Longitudinal Goals of Care**

References

Tweet 2 Reference:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Myeloma (v1.2025). Updated September 17, 2024. Accessed September 29, 2024.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Additional References:

Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. *J Clin Oncol*. 2021;40:2901-2912. doi:10.1200/JCO.21.01935

Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. *Blood*. 2023;142 (suppl 1):4. doi:10.1182/blood-2023-177546

Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. *Lancet Haematol*. 2022;9:E810-E821. doi:10.1016/S2352-3026(22)00263-0

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Myeloma (v1.2025). Updated September 17, 2024. Accessed September 29, 2024.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Paul B, Anwer F, Raza S, et al. Comparative meta-analysis of triplet vs quadruplet induction regimens in newly diagnosed, treatment naïve, multiple myeloma. *Cancers*. 2024;16:2938. doi:10.3390/cancers16172938

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024; 390:301-313.
doi:<https://doi.org/10.1056/NEJMoa2312054>

Sonneveld P, Moreau P, Dimopoulos M, et al. Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the PERSEUS trial. EHA 2024. Abstract S201. <https://library.ehaweb.org/eha/2024/eha2024-congress/422305>

Glossary

AEs, adverse events
CD, cluster of differentiation
Dara, daratumumab
Gr, grade
Isa, isatuximab
Ixa, ixazomib
KCy-d, carfilzomib, cyclophosphamide, dexamethasone
Kd, carfilzomib and dexamethasone
KRd, carfilzomib/lenalidomide, dexamethasone
mAb, monoclonal antibody
MM, multiple myeloma
N/A, not applicable
NCCN, National Comprehensive Cancer Network
NDMM, newly diagnosed multiple myeloma
NR, not reported
QOL, quality of life
R, lenalidomide
quad, quadruplet
TE, transplant eligible
URI, upper respiratory infection
V, bortezomib
VCy-d, bortezomib, cyclophosphamide, dexamethasone
VRd, bortezomib/lenalidomide/dexamethasone
VTD-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide
w/, with